在TRIMM-2研究中,talquetamab加daratumumab用于治疗复发性或耐火性多发性髓瘤
Ajai Chari1, Niels W C J van de Donk2, Bhagirathbhai Dholaria3
1Department of Hematology Oncology/Myeloma, University of California San Francisco, San Francisco, CA.
Blood
|September 22, 2025
概括
塔尔克塔马布与达拉图穆马布结合,在复发性/耐火性多发性髓瘤中显示出有前途的疗效. 这种组合疗法在重度预治疗的患者中导致了深度和持久的反应.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 复发性/耐药性多发性骨髓瘤 (R/R MM) 呈现出大量未满足的需求,特别是在对标准疗法的耐药性患者中.
- 针对G蛋白结合受体类C组5成员D (GPRC5D) 的两种特异性抗体提供了一种新的治疗方法.
- 达拉图马布是一种针对CD38的单克隆抗体,已在多发性骨髓瘤中表现出有效性.
研究的目的:
- 评估在R/RMM患者中将talquetamab与daratumumab结合使用的安全性和有效性.
- 在这个患者群体中评估应答率,应答持续时间和无进展生存期.
主要方法:
- 第1b期TRIMM-2研究招募了R/RMM患者,这些患者之前至少接受过3种疗法或是双重耐药.
- 患者接受了皮下talquetamab (0.4毫克/公斤每周或0.8毫克/公斤每隔一周) 加上daratumumab.
- 安全性是主要终点;整体反应,反应持续时间和无进展生存率是次要/探索性终点.
主要成果:
- 65名重度预治疗的患者 (中位数为5个先前的治疗线) 接受了组合治疗.
- 总体响应率很高:每周服用talquetamab队列中的71.4%,每隔一周服用talquetamab队列中的82.4%.
- 无进展生存时间的中位数为23.3个月 (每周一次) 和21.2个月 (每隔一周一次).
- 常见的不良事件包括口腔和皮肤事件,细胞因子释放综合征和感染; 81.5%的患者经历了3/4级事件.
结论:
- 塔尔基塔马布加达拉图穆马布在重度预治疗R / RMM的患者中显示出有希望的疗效,包括深度和持久的反应.
- 每种药物的安全性概况与单一治疗相一致.
- 药理动力学数据表明,达拉图穆马布可能通过调节免疫微环境来增强塔尔克塔马布的疗效.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Therapeutic Drug Monitoring: Overview and Classification
312
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
312


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)